Loading…
Hosted by CCRM · 🇺🇸 US · EN-CA · 25 episodes
Established thought leaders with verified media credentials.
Hear from academic and industry experts sharing insider insights, information and trend forecasts for the cell and gene therapy industry. “Commercializing Living Therapies with CCRM” is brought to you by CCRM, a leader in developing, manufacturing and commercializing regenerative medicine-based technologies, and cell and gene therapies. Questions / comments? email: podcast@ccrm.ca.
CCRM hosts Commercializing Living Therapies with CCRM, a science show with 25 episodes published.
Featuring: Katy Spink, President and COO, Managing Partner, Dark Horse Consulting Group Craig Beasley, Chief Technology Officer (CMC & Device), BlueRock Therapeutics *** Chemistry, Manufacturing, and Controls (CMC) is of
Featuring: Megan Munsie, PhD, Group Leader, Stem Cell Ethics & Policy, Stem Cell Medicine, Murdoch Children's Research Institute; Prepare Theme Lead, Novo Nordisk Foundation Center for Stem Cell Medicine, reNEW; Professo
Featuring: Molly Shoichet, PhD, O.C., O. Ont., FRS, University Professor and Pamela & Paul Austin Chair in Precision & Regenerative Medicine, University of Toronto Audrey Greenberg, MBA, CEO & Founder, AG Capital Advisor
Reni Benjamin, Managing Director, Healthcare Equity Research at Citizens Brock Reeve, CEO and Co-founder, Eos BioInnovation *** In this episode of Commercializing Living Therapies with CCRM, host Krista Lamb speaks with
Featuring: Silvio Tiziani, CEO, CCRM Australia Sarah Callens, CTO, CCRM Nordic *** In this episode of Commercializing Living Therapies with CCRM, Silvio Tiziani, CEO, CCRM Australia, and Sarah Callens, CTO, CCRM Nordic,
Featuring: Durhane Wong-Rieger, PhD, President and CEO, Canadian Organization for Rare Disorders Jacqueline Barry, PhD, Chief Clinical Officer, Cell and Gene Therapy Catapult *** In this episode, we dive into the critica
Featuring: Paul Knoepfler, PhD, Professor of Cell Biology and Human Anatomy, UC Davis School of Medicine Amy Zarzeczny, PhD LLM, Associate Professor, Johnson Shoyama Graduate School of Public Policy, University of Regina
Featuring: Christopher P. Boone, PhD, Group Vice President, Research Services, Health & Life Sciences, Oracle Kenneth L. Harris, Chief Strategy Officer and Head of AI, OmniaBio Inc. *** We are excited to share the first
Featuring: Jacki Jenuth, PhD, Partner and COO, Lumira Ventures Robin Quirk, PhD MBA, Vice President, Technology Sourcing and Venture Development, CCRM *** In this episode, we explore the dynamics of venture capital (VC)
Featuring: Michael Rosu-Myles, PhD, Executive Director, Health Canada Josephine Lembong, PhD, Senior Manager, Science and Industry Affairs, Alliance for Regenerative Medicine *** Currently, there are more than 2,000 cell
Featuring: Sonia Sennik, Executive Director, Creative Destruction Lab Glenn MacLean, Director, Technology Sourcing and Venture Development, CCRM *** In many science-oriented fields, including regenerative medicine and ad
Featuring: Matthew Durdy, Chief Executive Officer, Cell and Gene Therapy Catapult Michael May, PhD, President and Chief Executive Officer, CCRM *** Public-private partnerships are collaborations between government agenci
Featuring: Matthew Miller, B.M.Sc., PhD, Director, Michael G. DeGroote Institute for Infectious Disease Research; Co-Director, Canadian Pandemic Preparedness Hub (CP2H), McMaster University Patrycja Thompson, PhD, Direct
Featuring: Mamatha Bhat MD, MSc, PhD, FRCPC Hepatologist & Co-Lead of Transplant AI initiative (TAI), Ajmera Transplant Program Scientist, Toronto General Hospital Research Institute, University Health Network Associate
Featuring: Tom Whitehead, Co-Founder, Emily Whitehead Foundation. Courtney Horvath, PhD, Global Head of Strategy, Planning & Operations, Translational Medicine, Novartis. In this episode, we hear from two parents who sup
Featuring: Dr. Joerg Krueger, Medical Director, CAR T-Cell Program, The Hospital for Sick Children. Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania Perelman School
Featuring: Mark Taylor, Director of Commercialization, University Health Network Dr. Irja Elliott Donaghue Technical & IP Specialist and Patent Agent, Notch Therapeutics In the past, there was little evidence to challeng
Featuring: Dr. Dolores Baksh, CEO of TAAV Biomanufacturing Solutions Susan Nichols, Chief Business Officer at ViroCell Biologics As the cell and gene therapy industry continues to grow rapidly, Dolores Baksh and Susan Ni
Featuring: Dr. Lise Munsie, Vice President, iPSC Technology Platform, CCRM Dr. Stephen Sullivan, Programme Manager, Global Alliance for iPSC Therapies (GAiT) Drs. Lise Munsie and Stephen Sullivan explore some of the bigg
Featuring: Dr. Qasim Rafiq, Associate Professor in Cell and Gene Therapy Bioprocess Engineering, University College London (UCL) Dr. Christine Allen, Vice-President, Ecosystem Development, adMare BioInnovations Drs. Chri
Dr. Matthew Miller
Community Development Director · Michael G. DeGroote Institute for Infectious Disease Research
1 appearance on this show
Tom Whitehead
Practicing Psychotherapist · Emily Whitehead Foundation
1 appearance on this show
Bruce Levine
PHD - Professor in Cancer Gene Therapy, University of Pennsylvania · University of Pennsylvania Perelman School of Medicine
1 appearance on this show
Mark Taylor
Senior Advisor of Corporate Services · Primary Engineering and Construction
1 appearance on this show
Christine Allen
Senior Vice President of Talent Acquisition & Corporate HR · adMare BioInnovations
1 appearance on this show
Chris McCabe
CEO and Executive Director · Institute of Health Economics
1 appearance on this show
Megan Munsie
Stem Cell Medicine, Murdoch Children's Research Institute
1 appearance on this show
Audrey Greenberg
AG Capital Advisors
1 appearance on this show
Molly Shoichet
University of Toronto
1 appearance on this show
Brock Reeve
Eos BioInnovation
1 appearance on this show
Reni Benjamin
Citizens
1 appearance on this show
Silvio Tiziani
CCRM Australia
1 appearance on this show
Detected from recent episode content. Sponsor presence is a real signal of listener purchasing power and show monetisation.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Commercializing Living Therapies with CCRM has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their science audience.
Commercializing Living Therapies with CCRM is hosted by CCRM. The show is categorised under science (life) and has published 25 episodes.
Commercializing Living Therapies with CCRM has published 25 episodes.
Commercializing Living Therapies with CCRM regularly covers science, life. It sits in the science category, with a life focus.
Commercializing Living Therapies with CCRM is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Commercializing Living Therapies with CCRM hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Commercializing Living Therapies with CCRM average 30 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Commercializing Living Therapies with CCRM's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 6 days ago.